15.82 million yuan! Review of tamsulosin hydrochloride sustained release capsule
-
Last Update: 2020-02-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In the evening of February 10, Kangenbei announced that its wholly-owned subsidiary, Hangzhou Kangenbei, had received the approval document for supplementary drug application issued by the State Food and Drug Administration on tamsulosin hydrochloride sustained release capsule, which passed the conformity evaluation of generic drugs The data showed that tamsulosin hydrochloride sustained-release capsule is a selective α 1-adrenergic receptor for the treatment of benign prostatic hyperplasia As of the date of this announcement, the manufacturers of tamsulosin hydrochloride sustained-release capsules that have passed the consistency evaluation of the State Food and drug administration have
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
